Cyclerion Therapeutics Inc (CYCN) — Cash Flow-to-Debt Ratio
Cyclerion Therapeutics Inc (CYCN) has a Cash Flow-to-Debt Ratio of -0.69x as of March 2026, meaning its operating cash flow of $-1.18 Million could theoretically repay -1% of its total liabilities ($1.71 Million) in one year. Explore Cyclerion Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cyclerion Therapeutics Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Cyclerion Therapeutics Inc across 10 annual periods. Also explore how large is Cyclerion Therapeutics Inc's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Cyclerion Therapeutics Inc (2016–2025)
Year-by-year debt coverage analysis for Cyclerion Therapeutics Inc. For market capitalisation and broader financial context, see Cyclerion Therapeutics Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.68x | $-3.31 Million | $900.00K | ▲ +38.4% |
| 2024 | -5.98x | $-4.33 Million | $725.00K | ▲ +41.3% |
| 2023 | -10.18x | $-21.25 Million | $2.09 Million | ▼ -91.3% |
| 2022 | -5.32x | $-40.61 Million | $7.63 Million | ▼ -61.6% |
| 2021 | -3.29x | $-36.52 Million | $11.09 Million | ▼ -154.0% |
| 2020 | -1.30x | $-72.49 Million | $55.88 Million | ▼ -12.6% |
| 2019 | -1.15x | $-102.22 Million | $88.75 Million | ▲ +78.9% |
| 2018 | -5.46x | $-97.50 Million | $17.85 Million | ▲ +5.6% |
| 2017 | -5.79x | $-81.22 Million | $14.04 Million | ▼ -23.4% |
| 2016 | -4.69x | $-49.87 Million | $10.64 Million | — |